Gildeuretinol acetate is under clinical development by Alkeus Pharmaceuticals and currently in Phase II for Juvenile Macular Degeneration (Stargardt Disease). According to GlobalData, Phase II drugs for Juvenile Macular Degeneration (Stargardt Disease) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Gildeuretinol acetate LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Gildeuretinol acetate overview
Alkeus Pharmaceuticals overview
Alkeus Pharmaceuticals (Alkeus Pharma) is a clinical stage biopharmaceutical company. The company involves on discovery and development of treatments for eye disease. It lead drug candidate ALK-001, an orally delivered compound used for the treatment of Stargardt disease. Alkeus Pharma is conducting its clinical trials on diseases such as Intermediate dry-AMD, Autosomal Recessive Retinitis Pigmentosa and Autosomal Recessive Cone-Rod Dystrophy among others. The company also develops novel therapeutic drugs for patients suffering from Leber’s hereditary optic neuropathy. Alkeus Pharma is headquartered in Somerville, Massachusetts, the US.
For a complete picture of Gildeuretinol acetate’s drug-specific PTSR and LoA scores, buy the report here.